TW202320797A - 使用vps34抑制劑之組合療法 - Google Patents

使用vps34抑制劑之組合療法 Download PDF

Info

Publication number
TW202320797A
TW202320797A TW111130481A TW111130481A TW202320797A TW 202320797 A TW202320797 A TW 202320797A TW 111130481 A TW111130481 A TW 111130481A TW 111130481 A TW111130481 A TW 111130481A TW 202320797 A TW202320797 A TW 202320797A
Authority
TW
Taiwan
Prior art keywords
pyridin
alkyl
group
trifluoromethyl
methyl
Prior art date
Application number
TW111130481A
Other languages
English (en)
Chinese (zh)
Inventor
雅絲敏 于
馬丁 安德森
丹尼爾 L 佛林
瑪杜米塔 博格丹
Original Assignee
美商迪賽孚爾製藥有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 美商迪賽孚爾製藥有限公司 filed Critical 美商迪賽孚爾製藥有限公司
Publication of TW202320797A publication Critical patent/TW202320797A/zh

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7084—Compounds having two nucleosides or nucleotides, e.g. nicotinamide-adenine dinucleotide, flavine-adenine dinucleotide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
TW111130481A 2021-08-13 2022-08-12 使用vps34抑制劑之組合療法 TW202320797A (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202163232983P 2021-08-13 2021-08-13
US63/232,983 2021-08-13
US202263317500P 2022-03-07 2022-03-07
US63/317,500 2022-03-07

Publications (1)

Publication Number Publication Date
TW202320797A true TW202320797A (zh) 2023-06-01

Family

ID=83188606

Family Applications (1)

Application Number Title Priority Date Filing Date
TW111130481A TW202320797A (zh) 2021-08-13 2022-08-12 使用vps34抑制劑之組合療法

Country Status (7)

Country Link
US (1) US20250127790A1 (cg-RX-API-DMAC7.html)
EP (1) EP4384180A1 (cg-RX-API-DMAC7.html)
JP (1) JP2024532780A (cg-RX-API-DMAC7.html)
AU (1) AU2022326573A1 (cg-RX-API-DMAC7.html)
CA (1) CA3228766A1 (cg-RX-API-DMAC7.html)
TW (1) TW202320797A (cg-RX-API-DMAC7.html)
WO (1) WO2023019259A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102708177B1 (ko) 2018-01-31 2024-09-23 데시페라 파마슈티칼스, 엘엘씨. 위장관 기질 종양의 치료를 위한 병용 요법
GB2630970A (en) * 2023-06-15 2024-12-18 Duke Street Bio Ltd PARP1 inhibitor compounds

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CU24377B1 (es) * 2013-05-18 2018-12-05 Aduro Biotech Inc Dinucléotidos de purina cíclicos y composiciones de los mismos útiles para inducir la producción de interferón de tipo i dependientes de sting
WO2015108881A1 (en) * 2014-01-14 2015-07-23 Millennium Pharmaceuticals, Inc. Heteroaryls and uses thereof
PT3416957T (pt) 2016-02-19 2020-09-25 Sprint Bioscience Ab Compostos 6-heterociclil-4-morfolin-4-ilpiridin-2-ona úteis para o tratamento do cancro e da diabetes
IL302356A (en) * 2017-08-23 2023-06-01 Sprint Bioscience Ab Pyridylpyridone compounds
PL3672948T3 (pl) * 2017-08-23 2022-12-05 Sprint Bioscience Ab Związki pirydynoamino-pirydonu i pirymidynoamino-pirydonu
WO2020008046A1 (en) * 2018-07-06 2020-01-09 Sprint Bioscience Ab Biomarker

Also Published As

Publication number Publication date
EP4384180A1 (en) 2024-06-19
CA3228766A1 (en) 2023-02-16
AU2022326573A1 (en) 2024-02-15
WO2023019259A1 (en) 2023-02-16
US20250127790A1 (en) 2025-04-24
JP2024532780A (ja) 2024-09-10

Similar Documents

Publication Publication Date Title
JP7021282B2 (ja) 癌関連障害の治療のためのアゾロピリミジン
JP7394831B2 (ja) ピリドンa2rアンタゴニスト
JP7189155B2 (ja) 癌関連障害の治療のためのキナゾリン-ピラゾール誘導体
TWI535442B (zh) A nitrogen-containing heterocyclic compound having an action of inhibiting the production of canine erythritine
US11548867B2 (en) Amido compounds as AhR modulators
US8859768B2 (en) Heteroaryls and uses thereof
MD3523302T2 (ro) Compuși pirazolo[1,5-a]piridină substituiți în calitate de inhibitori ai RET kinazei
JP2022507231A (ja) がんの処置のためのHPK1阻害剤としての2,3-ジヒドロ-1H-ピロロ[3,4-c]ピリジン-1-オン誘導体
TW201713641A (zh) 經取代之喹喏啉衍生物
US20230055741A1 (en) Functionalized heterocyclic compounds as modulators of stimulator of interferon genes (sting)
EA029473B1 (ru) Применение ингибиторов pi3k для лечения острой и церебральной малярии
JP2017537080A (ja) 免疫調節剤
JP6859549B2 (ja) 医薬品活性を有するヘテロアリール化合物
US11530220B2 (en) Substituted imidazo[1,5-a]pyrazines and [1,2,4]triazolo[4,3-a]pyrazines for the modulation of AhR
CN103565653A (zh) 取代的吡唑酮化合物及其使用方法和用途
JP2021529806A (ja) 治療用複素環式化合物
TW202237109A (zh) Vps34抑制劑之抗病毒活性
US20250127790A1 (en) Combination therapy using vps34 inhibitors
CN117241800A (zh) Vps34抑制剂的抗病毒活性
TW202339730A (zh) Gcn2及perk激酶抑制劑及其使用方法
TW202542128A (zh) Vps34抑制劑及其使用方法
TW202523302A (zh) 噻唑化合物及其使用方法
CN118201619A (zh) Vps34抑制剂与sting激动剂的组合疗法用于治疗癌症
JP2014530202A (ja) コリンキナーゼ阻害剤として有用な化合物
TWI565702B (zh) 取代的吡唑酮化合物及其使用方法